Can Jevity Tube Feeding Contribute to Elevated Liver Function Tests?
Yes, Jevity and other enteral nutrition formulas can contribute to elevated liver function tests, though this occurs far less frequently than with parenteral nutrition—approximately 17% of enteral nutrition patients develop LFT abnormalities compared to 41% with parenteral nutrition. 1
Evidence for Enteral Nutrition-Associated Liver Dysfunction
The relationship between tube feeding and liver enzyme elevations is well-documented but significantly less problematic than parenteral nutrition:
Incidence and Pattern
- Enteral nutrition causes LFT abnormalities in approximately 17-50% of patients receiving prolonged tube feeding 2, 1
- These elevations typically appear after 21-25 days of continuous enteral feeding 2, 1
- The abnormalities are usually self-limited, with 40% resolving spontaneously even while continuing enteral nutrition 1
- Importantly, no cases of severe cholestatic jaundice have been reported with enteral nutrition, unlike the 8.5% incidence seen with parenteral nutrition 1
Clinical Characteristics
When LFT elevations occur with tube feeding like Jevity:
- Alkaline phosphatase may paradoxically decrease in some patients (seen in 7 patients at 21±13 days after starting tube feeding) 2
- Elevations are typically mild to moderate rather than severe 3
- The pattern shows hepatocellular predominance (elevated transaminases) more commonly than cholestatic pattern 3
- Steatosis or portal triaditis may be seen on biopsy if performed 3
Risk Factors and Contributing Elements
The development of LFT abnormalities during enteral nutrition appears largely independent of nutritional factors themselves 2, 4:
- Not related to caloric load or composition of the formula diet 2
- Not related to pre-existing nutritional status 1
- Systemic factors are more important: septic shock, hyperglycemia, and elevated creatinine are strongly associated with LFT elevations 4
Key Clinical Pitfall
Do not assume elevated LFTs are from the tube feeding alone—always investigate for:
- Sepsis or systemic infection (strongest association) 4
- Medications (including over-the-counter and herbal products) 5
- Pre-existing liver disease 6, 7
- Biliary obstruction or cholecystitis 3
Management Approach
When LFT abnormalities develop during Jevity tube feeding:
Continue enteral nutrition in most cases 8—the guidelines strongly support tube feeding even in patients with liver disease, as the benefits outweigh risks
Add oral/enteral intake if possible to reduce reliance on continuous tube feeding 4
Rule out other causes systematically:
Monitor but don't panic—most elevations resolve spontaneously or remain stable 2, 1
Consider cyclic feeding rather than continuous infusion if abnormalities persist 3
Important Context from Guidelines
The ESPEN guidelines on enteral nutrition in liver disease 8 actually recommend tube feeding for patients with existing liver disease, including those with cirrhosis and varices. This underscores that:
- Tube feeding is safer than parenteral nutrition for liver function 8, 9
- Benefits of nutritional support outweigh the risk of LFT abnormalities in malnourished patients 8
- Even patients with advanced liver disease should receive enteral nutrition when oral intake is inadequate 8
The bottom line: While Jevity can contribute to elevated LFTs in 17-50% of patients, these elevations are typically mild, self-limited, and far less concerning than the severe cholestatic complications seen with parenteral nutrition. Continue the tube feeding while investigating other causes, particularly infection and medications.